EUVIMEDEUVIMED entdecken
Open Access

Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors

Nihong Guo, Chong Huang, Jingxin Qiao, Yueyue Li, Yifei Wang, Anjie Xia, Guo Zhang, Zhen Fang, Jing You, Linli Li

Bioorganic & Medicinal Chemistry Letters · 2023

DOI: 10.1016/j.bmcl.2023.129238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023. Verfasst von Nihong Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichu…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing COVID-19 pandemic has led to massive infections and deaths and caused tremendous grief among the people. Although vaccines have played an important role in fighting COVID-19, the situation that the protective effect of current vaccines significantly decreases against mutated strains reminds us of the pressing need for developing effective antiviral therapeutics. The main protease (Mpro) is a key enzyme for SARS-CoV-2 viral replication and transcription and an attractive target for drug development. In this research, we report a new series of Mpro inhibitors containing 3-phenyl-1,2,4-oxadiazole. Structure-activity relationship (SAR) studies led to the discovery of the most active compound, 16d, which showed an IC50 value of 5.27 ± 0.26 μM. Collectively, we obtained a new small molecular inhibitor targeting SARS-CoV-2 Mpro, which contains a new scaffold. This compound could be taken as a lead compound for subsequent drug discovery against SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2PandemicsProtease InhibitorsAntiviral AgentsMolecular Docking SimulationCoronavirus 3C Proteases

Stichwörter der Autor:innen

3-phenyl-1,2,4-oxadiazole derivativesMain protease inhibitorSARS-CoV-2

Substanzen

Protease InhibitorsAntiviral Agents3C-like proteinase, SARS-CoV-2Coronavirus 3C Proteases

Autor:innen und Institutionen

  • Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China.
  • State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
  • Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China. Electronic address: lilinli@scu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, N., Huang, C., Qiao, J., Li, Y., Wang, Y., Xia, A., Zhang, G., Fang, Z., You, J., & Li, L. (2023). Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2023.129238

Vancouver

Guo N, Huang C, Qiao J, Li Y, Wang Y, Xia A, et al. Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 2023. doi:10.1016/j.bmcl.2023.129238

BibTeX
@article{Guo2023,
  author = {Guo, Nihong and Huang, Chong and Qiao, Jingxin and Li, Yueyue and Wang, Yifei and Xia, Anjie and Zhang, Guo and Fang, Zhen and You, Jing and Li, Linli},
  title = {Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2023},
  doi = {10.1016/j.bmcl.2023.129238}
}
Kostenlos starten →